Covishield and Covaxin have been fully authorised only for use in adults, and can only be used in a ‘programmatic setting’, which means you’ll still have to register on CoWin.
Approval was granted under New Drugs & Clinical Trials Rules, 2019 citing conditions that Bharat Biotech & SII will submit clinical trials' data & vaccines will be supplied for programmatic setting.
Bharat Biotech's Covaxin is currently priced at Rs 1,200 per dose while SII's Covishield costs Rs 780 at private facilities. Both the vaccines are only authorised for emergency use.
Serum Institute & Bharat Biotech's Covid vaccines, currently authorised only for emergency use in India, were granted approval by DCGI on certain conditions, official source said.
Bharat Biotech said a study at Emory University demonstrated that people who got a Covaxin booster, 6 months after the two doses, witnessed neutralising of the two Covid variants.
Study, which is yet to be peer-reviewed, was published on preprint portal medRxiv Saturday. It was conducted by Bharat Biotech and ICMR, which co-developed the vaccine.
First-of-its-kind study in India looked at reinfection rates among 4,978 healthcare workers, who had tested positive for Covid between 3 March 2020 and 18 June 2021.
Canada faces serious foreign interference issues, but these challenges must not be weaponized to unfairly target friendly and important allies like India.
In Episode 1544 of CutTheClutter, Editor-in-Chief Shekhar Gupta looks at some top economists pointing to the pitfalls of ‘currency nationalism’ with data from 1991 to 2004.
The decorated Naga officer from Manipur also served as envoy to Myanmar & Nagaland chief secy. Defence Minister Rajnath Singh inaugurated a museum dedicated to the Tawang hero Thursday.
While we talk much about our military, we don’t put our national wallet where our mouth is. Nobody is saying we should double our defence spending, but current declining trend must be reversed.
COMMENTS